The potential for fusions to inactivate critical tumor-suppressor genes is supported by the recent description of LOF rearrangements in TP53 in osteosarcoma [19], and suggests that such events may add to mutation, deletion, and epigenetic gene silencing as an important path of tumor-suppressor inactivation. The gene discussed is TP53; the disease is neoplasm.